

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * V-Sciences Investments Pte Ltd		2. Issuer Name and Ticker or Trading Symbol VICAL INC [VICL]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ Director <input checked="" type="checkbox"/> 10% Owner ____ Officer (give title below) ____ Other (specify below)	
(Last) (First) (Middle) 60B ORCHARD ROAD #06-18, TOWER 2, THE ATRIUM@ORCHARD		3. Date of Earliest Transaction (Month/Day/Year) 04/28/2009			
(Street) SINGAPORE, U0 238891		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) ____ Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)				Price
Common Shares	04/28/2009		S		200,000	D	\$ 2.5287 (1)	4,780,079	D (2)	
Common Shares	04/29/2009		S		122,410	D	\$ 2.2794 (3)	4,657,669	D (2)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
V-Sciences Investments Pte Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891		X		
Temasek Life Sciences Private LTD 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891		X		

Fullerton Management Pte Ltd 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891		X		
TEMASEK HOLDINGS (PRIVATE) LTD 60B ORCHARD ROAD #06T-18, TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0 238891		X		

Signatures

/s/ Lena Chia Yue Joo, Managing Director, Legal & Regulations, Temasek Holdings (Private) Limited		04/30/2009
<small>**Signature of Reporting Person</small>		Date
/s/ Cheo Hock Kuan, Director, Temasek Life Sciences Private Limited		04/30/2009
<small>**Signature of Reporting Person</small>		Date
/s/ Lena Chia Yue Joo, Director, Fullerton Management Pte Ltd		04/30/2009
<small>**Signature of Reporting Person</small>		Date
/s/ Choo Soo Shen Christina, Director, V-Sciences Investments Pte Ltd		04/30/2009
<small>**Signature of Reporting Person</small>		Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- Represents the weighted average price of 451 different transactions. Actual sale prices ranged from \$2.32 to \$2.90 per share. The reporting person will provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, information regarding the number of shares of common stock, \$0.01 par value per share, which are the subject of this filing (the "Shares"), sold at each price within the range.
- Temasek Holdings (Private) Limited, is the parent of Fullerton Management Pte Ltd, which is the parent of Temasek Life Sciences Private Limited, which is the parent of V-Sciences Investments Pte Ltd (the designated filer), which directly owns the Shares. Because of the foregoing relationships, the direct and indirect parents of V-Sciences Investments Pte Ltd may be deemed to beneficially own the Shares.
- (1) Represents the weighted average price of 271 different transactions. Actual sale prices ranged from \$2.17 to \$2.51 per share. The reporting person will provide to the issuer, any shareholder of the issuer, or the Staff, upon request, information regarding the number of Shares sold at each price within the range.
- (2) Represents the weighted average price of 451 different transactions. Actual sale prices ranged from \$2.32 to \$2.90 per share. The reporting person will provide to the issuer, any shareholder of the issuer, or the Staff, upon request, information regarding the number of shares of common stock, \$0.01 par value per share, which are the subject of this filing (the "Shares"), sold at each price within the range.
- (3) Represents the weighted average price of 271 different transactions. Actual sale prices ranged from \$2.17 to \$2.51 per share. The reporting person will provide to the issuer, any shareholder of the issuer, or the Staff, upon request, information regarding the number of Shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.